Food Allergy Program
Peanut Allergy
Key Facts
About Hal Allergy
HAL Allergy is a well-established, private European leader in allergen immunotherapy (AIT), with a 65-year history. The company operates a fully integrated model from R&D to commercial distribution, with a current portfolio of approved AIT products for respiratory allergies and a promising clinical pipeline targeting both respiratory and food allergies. Positioned in the Leiden Bio Science Park, HAL Allergy leverages proprietary technology to develop modified allergen extracts, aiming to address the growing global burden of allergic diseases through its therapeutic innovations.
View full company profileAbout Hal Allergy
HAL Allergy is a well-established, private European leader in allergen immunotherapy (AIT), with a 65-year history. The company operates a fully integrated model from R&D to commercial distribution, with a current portfolio of approved AIT products for respiratory allergies and a promising clinical pipeline targeting both respiratory and food allergies. Positioned in the Leiden Bio Science Park, HAL Allergy leverages proprietary technology to develop modified allergen extracts, aiming to address the growing global burden of allergic diseases through its therapeutic innovations.
View full company profileTherapeutic Areas
Other Peanut Allergy Drugs
| Drug | Company | Phase |
|---|---|---|
| PRT120 | Prota Therapeutics | Phase 3 |
| INP20 | InnoUp | Clinical |
| Peanut allergy program | Desentum | Unknown |
| Peanut Oral Immunotherapy | Camallergy | Phase 2 |
| INT301 (implied) | Intrommune Therapeutics | Pre-clinical |
| Ukko-Peanut | Ukko | Preclinical |
| VLP Peanut (VLP-p) | Allergy Therapeutics | Phase II |